Linda Mol

4.2k total citations · 1 hit paper
45 papers, 2.7k citations indexed

About

Linda Mol is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Linda Mol has authored 45 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Linda Mol's work include Colorectal Cancer Treatments and Studies (36 papers), Gastric Cancer Management and Outcomes (15 papers) and Genetic factors in colorectal cancer (12 papers). Linda Mol is often cited by papers focused on Colorectal Cancer Treatments and Studies (36 papers), Gastric Cancer Management and Outcomes (15 papers) and Genetic factors in colorectal cancer (12 papers). Linda Mol collaborates with scholars based in Netherlands, United States and Denmark. Linda Mol's co-authors include Cornelis J.A. Punt, Miriam Koopman, Ninja Antonini, C. J. Rodenburg, Frans Erdkamp, Harm Sinnige, Otilia Dalesio, Allert H. Vos, Jolanda Schrama and Annemieke Cats and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Linda Mol

45 papers receiving 2.7k citations

Hit Papers

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Co... 2009 2026 2014 2020 2009 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
    2009 1.0k citations Jolien Tol, Miriam Koopman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Linda Mol Netherlands 20 2.2k 920 627 555 506 45 2.7k
Cristina Granetto Italy 16 2.4k 1.1× 944 1.0× 994 1.6× 524 0.9× 553 1.1× 64 2.9k
Félix Couture Canada 12 2.7k 1.2× 1.1k 1.2× 945 1.5× 397 0.7× 533 1.1× 45 3.3k
Guy A. Van Hazel Australia 18 1.9k 0.8× 913 1.0× 909 1.4× 373 0.7× 357 0.7× 40 2.4k
Jean-Luc Canon Belgium 15 2.3k 1.0× 1.1k 1.2× 486 0.8× 522 0.9× 330 0.7× 31 2.8k
Akihito Tsuji Japan 24 1.9k 0.8× 1.6k 1.7× 325 0.5× 358 0.6× 671 1.3× 184 2.8k
Ralph Wong Canada 18 2.8k 1.3× 1.2k 1.3× 953 1.5× 487 0.9× 513 1.0× 36 3.4k
Pilar García‐Alfonso Spain 26 2.6k 1.2× 891 1.0× 364 0.6× 747 1.3× 477 0.9× 148 3.1k
C.-H. Köhne Germany 20 1.6k 0.7× 608 0.7× 670 1.1× 303 0.5× 427 0.8× 48 2.1k
Giacomo Allegrini Italy 23 3.2k 1.4× 1.2k 1.3× 1.2k 2.0× 573 1.0× 651 1.3× 77 3.9k
Silvana Chiara Italy 16 2.5k 1.1× 922 1.0× 914 1.5× 570 1.0× 702 1.4× 36 3.0k

Countries citing papers authored by Linda Mol

Since Specialization
Citations

This map shows the geographic impact of Linda Mol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda Mol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda Mol more than expected).

Fields of papers citing papers by Linda Mol

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linda Mol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda Mol. The network helps show where Linda Mol may publish in the future.

Co-authorship network of co-authors of Linda Mol

This figure shows the co-authorship network connecting the top 25 collaborators of Linda Mol. A scholar is included among the top collaborators of Linda Mol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda Mol. Linda Mol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hoorn, Sanne ten, Linda Mol, Dirkje W. Sommeijer, et al.. (2022). Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 22(1). 67–75. 4 indexed citations
2.
Hoorn, Sanne ten, Cynthia Waasdorp, Martijn G.H. van Oijen, et al.. (2022). Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer. BMC Cancer. 22(1). 394–394. 7 indexed citations
3.
Nanou, Afroditi, Linda Mol, Frank Coumans, et al.. (2020). Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer. Cells. 9(12). 2688–2688. 13 indexed citations
4.
Baas, Jara M., Stefan Böhringer, Linda Mol, et al.. (2018). Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. PLoS ONE. 13(12). e0208080–e0208080. 6 indexed citations
5.
May, Anne M., Hendrik Koffijberg, Harm van Tinteren, et al.. (2017). Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer. European Journal of Cancer. 75. 204–212. 19 indexed citations
6.
Kwakman, Johannes J.M., Lieke H. J. Simkens, Johan M. van Rooijen, et al.. (2017). Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Annals of Oncology. 28(6). 1288–1293. 47 indexed citations
7.
Punt, Cornelis J.A., Lieke H. J. Simkens, Johan van Rooijen, et al.. (2016). Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): The SALTO study of the Dutch Colorectal Cancer Group.. Journal of Clinical Oncology. 34(15_suppl). 3640–3640. 2 indexed citations
8.
9.
10.
Huiskens, Joost, Thomas M. van Gulik, Krijn P. van Lienden, et al.. (2015). Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases: The randomized phase III CAIRO5 study of the Dutch Colorectal Cancer Group.. Journal of Clinical Oncology. 33(15_suppl). TPS3622–TPS3622. 2 indexed citations
11.
12.
Venderbosch, Sabine, Johannes H.W. de Wilt, Steven Teerenstra, et al.. (2012). Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature. Indian Journal of Surgical Oncology. 3(1). 57–65. 7 indexed citations
13.
Simkens, Lieke H. J., Miriam Koopman, Linda Mol, et al.. (2011). Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. European Journal of Cancer. 47(17). 2560–2567. 74 indexed citations
14.
Venderbosch, Sabine, Johannes H.W. de Wilt, Steven Teerenstra, et al.. (2011). Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature. Annals of Surgical Oncology. 18(12). 3252–3260. 125 indexed citations
15.
Iersel, L.B.J. van, Miriam Koopman, Cornelis J.�H. van de Velde, et al.. (2010). Management of isolated nonresectable liver metastases in colorectal cancer patients: a case–control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. Annals of Oncology. 21(8). 1662–1667. 17 indexed citations
16.
Koopman, Mmw, et al.. (2010). 異時性対同時性転移性結腸直腸癌(CRC)における臨床像と病理像. Annals of Oncology. 21. 65. 13 indexed citations
17.
18.
Iersel, Liselot Valkenburg‐van, Cornelis J.�H. van de Velde, Linda Mol, et al.. (2009). 6054 Management of isolated non-resectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. European Journal of Cancer Supplements. 7(2). 337–338. 2 indexed citations
19.
Simkens, Lieke H. J., Jolien Tol, Miriam Koopman, et al.. (2008). Current Questions in the Treatment of Advanced Colorectal Cancer: The CAIRO Studies of the Dutch Colorectal Cancer Group. Clinical Colorectal Cancer. 7(2). 105–109. 6 indexed citations
20.
Thé, Bertram, Linda Mol, Ron L. Diercks, Peter M. A. van Ooijen, & Nico Verdonschot. (2006). Correction of Error in Two-dimensional Wear Measurements of Cemented Hip Arthroplasties. Clinical Orthopaedics and Related Research. 442. 180–186. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cristina Granetto Breakdown of academic impact, for papers by Félix Couture Breakdown of academic impact, for papers by Guy A. Van Hazel Breakdown of academic impact, for papers by Jean-Luc Canon Breakdown of academic impact, for papers by Akihito Tsuji Breakdown of academic impact, for papers by Ralph Wong Breakdown of academic impact, for papers by Pilar García‐Alfonso Breakdown of academic impact, for papers by C.-H. Köhne Breakdown of academic impact, for papers by Giacomo Allegrini Breakdown of academic impact, for papers by Silvana Chiara
Rankless by CCL
2026